827 related articles for article (PubMed ID: 20804570)
21. A qualitative transcriptional signature to reclassify histological grade of ER-positive breast cancer patients.
Li J; Jiang W; Liang Q; Liu G; Dai Y; Zheng H; Yang J; Cai H; Zheng G
BMC Genomics; 2020 Apr; 21(1):283. PubMed ID: 32252627
[TBL] [Abstract][Full Text] [Related]
22. Breast cancer special types: why bother?
Reis-Filho JS; Lakhani SR
J Pathol; 2008 Dec; 216(4):394-8. PubMed ID: 18798222
[TBL] [Abstract][Full Text] [Related]
23. New Advances in Molecular Breast Cancer Pathology.
Rakha EA; Pareja FG
Semin Cancer Biol; 2021 Jul; 72():102-113. PubMed ID: 32259641
[TBL] [Abstract][Full Text] [Related]
24. Enrichment of high-grade tumors in breast cancer gene expression studies.
van Seijen M; Mooyaart AL; Mulder L; Hoogstraat M; Drukker CA; Loo CE; Pouw B; Sonke GS; Wesseling J; Lips EH
Breast Cancer Res Treat; 2018 Apr; 168(2):327-335. PubMed ID: 29256013
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
[TBL] [Abstract][Full Text] [Related]
26. Molecular profiling assays in breast cancer: are we ready for prime time?
Gökmen-Polar Y; Badve S
Oncology (Williston Park); 2012 Apr; 26(4):350-7, 361. PubMed ID: 22655528
[TBL] [Abstract][Full Text] [Related]
27. An ensemble predictive modeling framework for breast cancer classification.
Nagarajan R; Upreti M
Methods; 2017 Dec; 131():128-134. PubMed ID: 28716511
[TBL] [Abstract][Full Text] [Related]
28. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.
Sotiriou C; Wirapati P; Loi S; Harris A; Fox S; Smeds J; Nordgren H; Farmer P; Praz V; Haibe-Kains B; Desmedt C; Larsimont D; Cardoso F; Peterse H; Nuyten D; Buyse M; Van de Vijver MJ; Bergh J; Piccart M; Delorenzi M
J Natl Cancer Inst; 2006 Feb; 98(4):262-72. PubMed ID: 16478745
[TBL] [Abstract][Full Text] [Related]
29. The molecular basis of breast cancer pathological phenotypes.
Heng YJ; Lester SC; Tse GM; Factor RE; Allison KH; Collins LC; Chen YY; Jensen KC; Johnson NB; Jeong JC; Punjabi R; Shin SJ; Singh K; Krings G; Eberhard DA; Tan PH; Korski K; Waldman FM; Gutman DA; Sanders M; Reis-Filho JS; Flanagan SR; Gendoo DM; Chen GM; Haibe-Kains B; Ciriello G; Hoadley KA; Perou CM; Beck AH
J Pathol; 2017 Feb; 241(3):375-391. PubMed ID: 27861902
[TBL] [Abstract][Full Text] [Related]
30. Classification and grading of invasive breast carcinoma.
Elston CW
Verh Dtsch Ges Pathol; 2005; 89():35-44. PubMed ID: 18035670
[TBL] [Abstract][Full Text] [Related]
31. New molecular classifications of breast cancer.
Cianfrocca M; Gradishar W
CA Cancer J Clin; 2009; 59(5):303-13. PubMed ID: 19729680
[TBL] [Abstract][Full Text] [Related]
32. A novel morphologic-molecular recurrence predictive model refines traditional prognostic tools for invasive breast carcinoma.
Ni YB; Tsang JY; Chan SK; Tse GM
Ann Surg Oncol; 2014 Sep; 21(9):2928-33. PubMed ID: 24743910
[TBL] [Abstract][Full Text] [Related]
33. Future prospects for the staging of breast cancer.
Rutgers EJ; Peterse HL
Semin Surg Oncol; 1996; 12(1):3-11. PubMed ID: 8821404
[TBL] [Abstract][Full Text] [Related]
34. The classification of invasive carcinoma of the breast.
Gannon LM; Cotter MB; Quinn CM
Expert Rev Anticancer Ther; 2013 Aug; 13(8):941-54. PubMed ID: 23984896
[TBL] [Abstract][Full Text] [Related]
35. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
[TBL] [Abstract][Full Text] [Related]
36. A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity.
Oh E; Choi YL; Park T; Lee S; Nam SJ; Shin YK
Breast Cancer Res Treat; 2012 Apr; 132(2):499-509. PubMed ID: 21667120
[TBL] [Abstract][Full Text] [Related]
37. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma.
Ayadi L; Khabir A; Amouri H; Karray S; Dammak A; Guermazi M; Boudawara T
World J Surg Oncol; 2008 Oct; 6():112. PubMed ID: 18945339
[TBL] [Abstract][Full Text] [Related]
38. Two-color, cytokeratin-labeled dna flow cytometric analysis of 332 breast cancers: lack of prognostic value with 12-year follow-up.
Prasad AR; Divine G; Zarbo RJ
Arch Pathol Lab Med; 2001 Mar; 125(3):364-74. PubMed ID: 11231485
[TBL] [Abstract][Full Text] [Related]
39. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
Ross JS
Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
[TBL] [Abstract][Full Text] [Related]
40. A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR
Zhang Y; Schroeder BE; Jerevall PL; Ly A; Nolan H; Schnabel CA; Sgroi DC
Clin Cancer Res; 2017 Dec; 23(23):7217-7224. PubMed ID: 28939745
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
